NeuroSigma prepares for Phase III trial of Monarch eTNS system

07/29/2013 | MassDevice.com (Boston)

NeuroSigma has secured FDA approval to start a Phase III clinical trial investigating the Monarch eTNS system for treatment of epilepsy. The device transmits an electrical pulse to the patient through a soft patch attached to the forehead. PET imaging confirmed the treatment targets epilepsy-affected regions. The company plans to conduct multicenter trials in the U.S., Europe and Canada.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC